The government of Ukraine has implemented a new treatment regimen for the most difficult-to-treat forms of TB, making a big leap in fighting drug-resistant TB. The preliminary results from the regime, a  six-month, all-oral treatment, called BPaL, consisting of bedaquiline, pretomanid and linezolid, warrant an expansion of access to this regimen.  Endorsed by the WHO for use under operational research conditions in patients with extensively drug-resistant tuberculosis, BPal regime  demonstrates that it can be highly cost-saving compared with conventional regimens to treat patients in high drug-resistant TB burden settings.